| Symbol | OLMA |
|---|---|
| Name | OLEMA PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 780 BRANNAN STREET, SAN FRANCISCO, California, 94103, United States |
| Telephone | +1 415 - 651-3316 |
| Fax | — |
| — | |
| Website | https://www.olema.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001750284 |
| Description | Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for womens cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. Additional info from NASDAQ: |
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more(90% Positive) OLEMA PHARMACEUTICALS, INC. (OLMA) Provides Update on strategy for metastatic castration-resistant prostate cancer
Read moreOlema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Read more(85% Positive) OLEMA PHARMACEUTICALS, INC. (OLMA) Provides Update on data for a poster presentation on May 30
Read moreOlema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Read moreNew Form SCHEDULE 13G/A - Olema Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001193125-26-226930 <b>Size:</b> 8 KB
Read moreNew Form SCHEDULE 13G/A - Olema Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001274173-26-000150 <b>Size:</b> 12 KB
Read more(80% Positive) OLEMA PHARMACEUTICALS, INC. (OLMA) Announces Enrollment Update for data Due to Patient Enrollment Issues, Safety Review, Efficacy Assessment
Read moreOlema Oncology Reports First Quarter 2026 Financial and Operating Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+… | Phase3 | Breast Cancer | Recruiting | 2025-11-03 | 2032-01-01 | ClinicalTrials.gov |
| NCT06784193 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | Phase1 | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | Recruiting | 2024-12-16 | 2027-08-30 | ClinicalTrials.gov |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Adva… | Phase3 | Breast Cancer | Recruiting | 2023-11-16 | 2027-09-30 | ClinicalTrials.gov |
| NCT05508906 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpeli… | Phase1 | Metastatic Breast Cancer | Recruiting | 2022-08-31 | 2028-01-31 | ClinicalTrials.gov |
| NCT05266105 | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Br… | Phase1 | Breast Cancer | Active_Not_Recruiting | 2021-12-10 | 2026-03-01 | ClinicalTrials.gov |
| NCT04505826 | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and… | Phase1 | Hormone Receptor Positive Breast Carcinoma | Completed | 2020-08-13 | 2024-07-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| OP-1250 | Other | Phase PHASE1 | Hormone Receptor Positive Breast Carcinoma | COMPLETED | NCT04505826 |
| OP-1250 | Other | Phase PHASE1 | Hormone Receptor Positive Breast Carcinoma | COMPLETED | NCT04505826 |
| OP-1250 | Other | Phase PHASE1 | Hormone Receptor Positive Breast Carcinoma | COMPLETED | NCT04505826 |
| OP-1250 | Other | Phase PHASE1 | Hormone Receptor Positive Breast Carcinoma | COMPLETED | NCT04505826 |
| OP-1250 | Other | Phase PHASE1 | Hormone Receptor Positive Breast Carcinoma | COMPLETED | NCT04505826 |
| OP-1250 | Other | Phase PHASE1 | Hormone Receptor Positive Breast Carcinoma | COMPLETED | NCT04505826 |
| OP-1250 | Other | Phase PHASE1 | Hormone Receptor Positive Breast Carcinoma | COMPLETED | NCT04505826 |
| Palazestrant | Other | Phase PHASE1 | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | RECRUITING | NCT06784193 |
| Fulvestrant | Other | Phase PHASE1 | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | RECRUITING | NCT06784193 |
| OP-3136 | Other | Phase PHASE1 | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | RECRUITING | NCT06784193 |
| Atirmociclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT05508906 |
| Everolimus | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT05508906 |
| Alpelisib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT05508906 |
| Ribociclib | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT05508906 |
| Palazestrant | Other | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT05508906 |
| Palbociclib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05266105 |
| Palazestrant | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05266105 |
| Exemestane | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT06016738 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT06016738 |
| Anastrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT06016738 |
| Fulvestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT06016738 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT06016738 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant matching-placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Ribociclib | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palazestrant | Other | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| VAL-083, Dianhydrogalactitol | DRUG | Phase PHASE1 | Ovarian Cancer | WITHDRAWN | NCT03281681 |
| Palazestrant matching-placebo | DRUG | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Letrozole-matching placebo | DRUG | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| OP-3136 | DRUG | Phase PHASE1 | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | RECRUITING | NCT06784193 |
| Exemestane | DRUG | Phase PHASE3 | Breast Cancer | RECRUITING | NCT06016738 |
| Letrozole | DRUG | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Anastrozole | DRUG | Phase PHASE3 | Breast Cancer | RECRUITING | NCT06016738 |
| Fulvestrant | DRUG | Phase PHASE1 | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | RECRUITING | NCT06784193 |
| Atirmociclib | DRUG | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT05508906 |
| Everolimus | DRUG | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT05508906 |
| Alpelisib | DRUG | Phase PHASE1 | Metastatic Breast Cancer | RECRUITING | NCT05508906 |
| Ribociclib | DRUG | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| Palbociclib | DRUG | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05266105 |
| Palazestrant | DRUG | Phase PHASE3 | Breast Cancer | RECRUITING | NCT07085767 |
| OP-1250 | DRUG | Phase PHASE1 | Hormone Receptor Positive Breast Carcinoma | COMPLETED | NCT04505826 |